The Cardiovascular Market Outlook to 2013

Competitive Landscape, Global Market Analysis and Pipeline Analysis

Publication Date	January 2009
Publisher	Business Insights
Product Type	Report
Pages	197
ISBN Number	not applicable
Product Code	RBI00274

Buy this product or for assistance call +44 20 7060 7474

PDF £2,305.00$3834 | €2580

FAX Order above formats by FAX

Summary

The cardiovascular therapy area spans a range of treatment classes including anti-hypertensives, anti-dyslipidemics, anti-thrombotics, hematological preparations and cardiac therapies. Each sub-therapy area is facing a different set of issues and challenges, such as the current generic threat for dyslipidemics and competition from novel therapies in thrombosis. Leading products in these sub-therapy areas have proven to be significant growth drivers for Big Pharma, such as Pfizer's Lipitor, Sanofi's Plavix and Lovenox, and Amgen's Aranesp. The recent emergence of smaller players and increased competition from generics has prompted leading players to engage in alliances and agreements for key drugs to keep pace with the changing market landscape.

'The Cardiovascular Market Outlook to 2013: Competitive landscape, global market analysis and pipeline analysis' is a new report published by Business Insights that provides comprehensive coverage of every class of drugs across major cardiovascular indications. Detailed insights into recent key events and future market leaders are also provided, in addition to epidemiological analysis and forecasts for major products over the 2007-13 period. With coverage of over 90% of the total market for cardiovascular products, this report profiles the underlying trends and factors driving the market and identifies the most promising areas of potential growth.

Discover the key market trends and growth drivers of the cardiovascular market, assess the competitive dynamics of leading companies and evaluate the future prospects of major products with this new report...

Some key findings from this report

Anti-hypertensives were the highest selling sub-therapeutic category in 2007, with global sales of $52.9bn. Norvasc was the leading anti-hypertensive, with sales of $3.3bn.
The global market for anticoagulants will experience significant activity over the next two years with the introduction of new drugs including Boehringer Ingelheim's Pradaxa/Rendix, Bayer- Schering/J&J's Xarelto, BMS/Pfizer's apixaban and Eli Lilly/Daiichi's Effient.
Crestor has been steadily gaining market share and positive JUPITER trial results will help to further improve its market position. The positive trial data is likely to result in recommended cholesterol treatment goals becoming lowered, and Crestor will be well positioned to capture more patients and expand the market.
GlaxoSmithKline's (GSK) acquisition of Reliant Pharma will contribute to GSK having the highest growth amongst the leading players through to 2013. The addition of key drugs such as Lovaza to GSK's portfolio will drive this growth.
The anti-arrhythmic market is expected to remain a relatively small opportunity, as drug therapy has significant limitations. Multaq from Sanofi-Aventis may become the therapeutic standard in the first-line treatment of chronic atrial fibrillation.

Top five reasons to order your copy today

Assess patient potential, treatment trends and sales patterns across major cardiovascular diseases over the period 2007-13 within the subtherapy areas of hypertension, dyslipidemia, thrombosis and stroke.
Measure the market performance and strategic positioning of major pharmaceutical corporations with this report's evaluation of the franchises and market shares of AstraZeneca, Amgen, BMS, Daiichi Sankyo, GSK, Merck, Novartis, Pfizer and Sanofi-Aventis.
Discover the market dynamics of the cardiovascular area and understand the impact of recent key events by assessing major market trends, growth drivers and the latest issues affecting R&D.
Compare the future prospects of key players and forecast sales of leading products across major indications to 2013 with this report's analysis of sales focus by drug class, currently marketed portfolios, R&D pipelines, and strategy/growth assessments.
Identify the strategies that offer the greatest success potential within the future cardiovascular market and understand the challenges currently facing companies within this therapeutic area.

Key issues examined in this report

Leading cholesterol-lowering drugs show declining sales. Patent expirations have been off-setting positive drivers of growth including recent trial results that support aggressive LDL lowering in broader patient populations. The availability of generic simvastatin has resulted in increased therapeutic substitution and declining brand share.
Stalling growth of leading hypertension drugs. Angiotensin receptor blockers or ARBs have become the most prescribed antihypertensive class. However after several years of gaining market, growth in the branded ARB category appears to be stalling. A number of studies have shown ARBs to be no more effective than generic ACE inhibitors, most recently the ONTARGET study published in April, 2008
Novel oral anti-thrombotics threaten leading drugs. Novel drugs in the thrombosis market pipeline are expected to strongly compete with the current market leader Lovenox . The new drugs are orally formulated and are expected to substantially expand the market. Trial data has shown these drugs to be more efficacious without presenting a huge inrease in the risk of bleeding.

Your questions answered

Which indications will experience the greatest growth in the global cardiovascular market over the period 2008-13?
Which companies will become the key players in the cardiovascular area over the period 2009 -13?
How have recent major product launches from companies such as Gilead and Novartis performed?
What is the forecast market size and growth rate over the period 2008-2013 across the major cardiovascular indications?
Which pipeline products offer the highest growth potential?
What will be the competitive landscape of hypertension, dyslipidemia, thrombosis, hematology and cardiac therapies in 2013?

Content

The Cardiovascular Market Outlook to 2013
Executive summary
Overview and epidemiology of cardiovascular disorders
Global market analysis
Pipeline analysis
Competitive landscape
Chapter 1 Scope and methodology
- Scope
- Methodology
Chapter 2 Overview and epidemiology of cardiovascular disorders
- Summary
- Introduction
- Predisposing factors
- Risk factors
- Hypertension
- Diagnosis, treatment and management
- Epidemiology
- Forecast epidemiology
- Dyslipidemia
- Diagnosis, treatment and management
- Epidemiology
- Forecast epidemiology
- Cardiovascular diseases
- Arteriosclerosis/atherosclerosis
- Thrombosis
- Cardiac arrhythmias
- Myocardial infarction
- Acute coronary syndrome (ACS)
- Congestive heart failure (CHF)
- Coronary artery disease (CAD)
- Peripheral artery disease (PAD)
- Pulmonary hypertension
- Angina pectoris
- Stroke
- Epidemiology
- Forecast epidemiology
Chapter 3 Global market analysis
- Summary
- Introduction
- Market analysis by country
- Licensing Trends
- Market analysis by drug class
- Leading brands dynamics
- Cardiovascular sales forecast to 2013
- Key events in the cardiovascular market
- Therapeutic substitution causing decline in sales of leading hypercholesterolemia drugs
- Genericization in the leading classes of hypertension drugs
- Tekturna/Rasilez launch slower than expected
- Generic Plavix in Germany represents moderate risk
- Regulatory delay for Prasugrel improve US Plavix outlook
- Safety concerns on ESAs to impact the multibillion dollar EPO franchises
- Anti-hypertensive treatments
- Introduction
- Anti-hypertensives drug classes
- Leading treatment brands by drug class
- Key brands analysis
- Norvasc
- Diovan
- Cozaar
- Sales forecast to 2013
- Anti-dyslipidemics
- Introduction
- Anti-dyslipidemics drug classes
- Leading treatment brands by drug class
- Key brands analysis
- Lipitor
- Vytorin
- Crestor
- Sales forecast to 2013
- Anti-thrombotics treatments
- Introduction
- Anti-thrombotics drug classes
- Leading treatment brands by drug class
- Key brands analysis
- Lovenox
- Plavix
- Sales forecast to 2013
- Hematological preparations
- Introduction
- Market analysis by drug class
- Leading treatment brands by drug class
- Key brands analysis
- Aranesp
- Sales forecast to 2013
- Cardiac therapies
- Introduction
- Market analysis by drug class
- Leading treatment brands by drug class
- Sales forecast to 2013
- Other cardiovascular agents
- Introduction
- Leading brands by drug class
- Key brands analysis
- Tracleer
- Sales forecast to 2013
Chapter 4 Pipeline analysis
- Summary
- Introduction
- Key events in the development of the cardiovascular pipeline
- Merck's Cordaptive/Tredaptive facing regulatory delay owing to safety concerns
- Persistent interest in drugs which increase HDL cholesterol levels
- Mipomersen from Genzyme may become a novel option for high cholesterol
- New treatments drive robust growth of the anticoagulants class
- Multaq may become the gold-standard as first-line treatment of chronic atrial fibrillation
- Bayer Schering/J&J's Xarelto demonstrates best in class characteristics
- Cytos Biotechnology reports encouraging results for its hypertension vaccine
- Novel reperfusion agent from Neurobiological Technologies presents significant commercial opportunity
- Cardiovascular pipeline
- Leading drugs in development
- Profiles of key pipeline products
- Recently marketed drugs
- Letairis
- Tekturna/Rasilez
- Drugs in registration
- Effient
- Multaq
- Xarelto
- TriLipix
- Pradaxa/Rendix
- Drugs in Phase III clinical studies
- Apixaban
- Cangrelor
- SCH 530348
- Ticagrelor
- Drugs in Phase II clinical studies
- E5555
- Pipeline forecast
Chapter 5 Competitive Landscape
- Summary
- Introduction
- Sales performance of leading players
- Detailed analysis of leading cardiovascular players
- Pfizer
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Sanofi-Aventis
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Merck
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Novartis
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Amgen
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- AstraZeneca
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Bristol-Myers Squibb
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Johnson and Johnson
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Daiichi Sankyo
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- GlaxoSmithKline
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
Chapter 6 Appendix
- Glossary
- Index
List of Figures
- Figure 2.1: Cardiovascular disease etiology
- Figure 2.2: Cardiovascular risk factors
- Figure 2.3: Definition and classification of hypertension
- Figure 2.4: Hypertension - treatment options
- Figure 2.5: Types of lipoproteins
- Figure 2.6: Interpretation of blood lipid levels
- Figure 2.7: LDL levels and therapy patterns
- Figure 3.8: Global cardiovascular market share by geography ($m), 2007
- Figure 3.9: Global sales of types of cardiovascular brands ($bn), 200607
- Figure 4.10: Prevailing R&D approaches, 2008
- Figure 4.11: Cardiovascular pipeline by indication and stage of development, 2008
- Figure 4.12: Leading recently marketed and late-stage R&D products in the cardiovascular market, 2008
- Figure 5.13: Sales of key players in the cardiovascular market, ($m), 2007
- Figure 5.14: Forecast sales of key players in the cardiovascular market, ($m), 2007
- Figure 5.15: Market share of key players by sales value, 2013
- Figure 5.16: Pfizer cardiovascular sales by drug class, ($bn), 2007
- Figure 5.17: Sanofi's cardiovascular sales by drug class, ($bn), 2007
- Figure 5.18: Merck cardiovascular sales by drug class, ($bn), 2007
- Figure 5.19: Novartis' cardiovascular sales by drug class, ($bn), 2007
- Figure 5.20: Amgen's cardiovascular sales by drug class, ($bn), 2007
- Figure 5.21: AstraZeneca's cardiovascular sales by drug class, ($bn), 2007
- Figure 5.22: BMS's cardiovascular sales by drug class, ($bn), 2007
- Figure 5.23: J&J's cardiovascular sales by drug class, ($bn), 2007
- Figure 5.24: Daiichi Sankyo's cardiovascular sales by drug class, ($bn), 2007
- Figure 5.25: GSK's cardiovascular sales by drug class, ($bn), 2007
- Table 2.1: Estimated prevalence of cardiovascular disorders across seven major markets (in thousands), 2007
- Table 2.2: Estimated prevalence of hypertension across the seven major markets (in thousands), 2007
- Table 2.3: Forecast epidemiology of hypertension across seven major markets (in thousands), 20072013
- Table 2.4: Estimated prevalence of dyslipidemia across the seven major markets (in thousands), 2007
- Table 2.5: Forecast epidemiology of dyslipidemia across the seven major markets (in thousands), 20072013
- Table 2.6: Estimated prevalence of stroke across the seven major markets (in thousands), 2007
- Table 2.7: Forecast epidemiology of stroke across the seven major markets (in thousands), 2007 2013
- Table 3.8: The global cardiovascular market by drug class ($m), 20062007
- Table 3.9: Leading brands in the global cardiovascular market ($m), 20062007
- Table 3.10: Cardiovascular market sales forecast by drug class ($m), 20072013
- Table 3.11: Leading anti-hypertensives treatments in the global cardiovascular market ($m), 2006 2007
- Table 3.12: Anti-hypertensives sales forecast ($m), 20072013
- Table 3.13: Leading anti-dyslipidemic treatments in the global cardiovascular market ($m), 2006 2007
- Table 3.14: Anti-dyslipidemics sales forecast ($m), 20072013
- Table 3.15: Leading anti-thrombotics treatments in the global cardiovascular market ($m), 2006- 2007
- Table 3.16: Anti-thrombotics sales forecast ($m), 20072013
- Table 3.17: Leading hematological preparations in the global cardiovascular market ($m), 2006 2007
- Table 3.18: Hematological preparations sales forecast ($m), 20072013
- Table 3.19: Leading cardiac therapies in the global cardiovascular market ($m), 20062007
- Table 3.20: Cardiac therapies sales forecast ($m), 20072013
- Table 3.21: Other cardiovascular treatments in the global cardiovascular market ($m), 20062007
- Table 3.22: Cardiovascular treatments sales forecast ($m), 20072013
- Table 4.23: An overview of Letairis
- Table 4.24: An overview of Tekturna/Rasilez
- Table 4.25: An overview of Effient
- Table 4.26: An overview of Multaq
- Table 4.27: An overview of Xarelto
- Table 4.28: An overview of TriLipix
- Table 4.29: An overview of Pradaxa
- Table 4.30: An overview of Apixaban
- Table 4.31: An overview of Cangrelor
- Table 4.32: An overview of SCH530348
- Table 4.33: An overview of Ticagrelor
- Table 4.34: An overview of E5555
- Table 4.35: Cardiovascular disorders pipeline forecast, ($m), 200813
- Table 5.36: Leading Players in the global cardiovascular market, ($m),
- Table 5.37: Pfizer's leading cardiovascular product portfolio, ($m), 200607
- Table 5.38: Pfizer's cardiovascular R&D product pipeline, 2007
- Table 5.39: Sanofi-Aventis' leading cardiovascular product portfolio, ($m), 200607
- Table 5.40: Sanofi-Aventis' cardiovascular R&D product pipeline, 2007
- Table 5.41: Merck's leading cardiovascular product portfolio, ($m), 200607
- Table 5.42: Merck's cardiovascular R&D product pipeline, 2007
- Table 5.43: Novartis' leading cardiovascular product portfolio, ($m), 200607
- Table 5.44: Novartis' cardiovascular R&D product pipeline, 2007
- Table 5.45: Amgen's cardiovascular R&D product pipeline, 2007
- Table 5.46: AstraZeneca's leading cardiovascular product portfolio, ($m), 200607
- Table 5.47: AstraZeneca's cardiovascular R&D product pipeline, 2007
- Table 5.48: BMS's leading cardiovascular product portfolio, ($m), 200607
- Table 5.49: BMS's cardiovascular R&D product pipeline, 2007
- Table 5.50: J&J's leading cardiovascular product portfolio, ($m), 200607
- Table 5.51: J&J's cardiovascular R&D product pipeline, 2007
- Table 5.52: Daiichi Sankyo's leading cardiovascular product portfolio, ($m),
- Table 5.53: Daiichi Sankyo's cardiovascular R&D product pipeline, 2007
- Table 5.54: GSK's leading cardiovascular product portfolio, ($m),
- Table 5.55: GSK's cardiovascular R&D product pipeline, 2007